U.S. Companion Animal Cardiac Pharmaceuticals Market (2025 - 2033)

Market Size & Trends

The U.S. companion animal cardiac pharmaceuticals market size was estimated at USD 776.29 million in 2024 and is projected reach USD 1,499.52 million by 2033, growing at a CAGR of 7.76% from 2025 to 2033. The key factors responsible for driving the market growth include the rising incidence of heart diseases in pets, increasing pet health expenditure, and increasing research and development.

For instance, according to an article published by Small Door Inc., Congestive heart failure (CHF) is relatively prevalent in dogs, affecting around 10% of the overall canine population and as many as 75% of older dogs who suffer from some form of heart disease.

The growing incidence of heart disease among companion animals is becoming a key driver in expanding veterinary cardiology services. As pets live longer due to general veterinary care, nutrition, and lifestyle improvements, they are more likely to develop chronic age-related conditions such as cardiovascular diseases. Veterinarians are increasingly diagnosing conditions such as valvular diseases, cardiomyopathies, and arrhythmias, which require specialized knowledge and treatment.

Veterinary cardiology has witnessed significant advancements in recent years, transforming how heart conditions in animals are diagnosed and treated. Innovations in diagnostic tools, surgical techniques, and therapeutic options are enhancing the precision of care and improving the outcomes and quality of life for pets. For instance, in April 2025, Auburn University's College of Veterinary Medicine performed a groundbreaking surgery on Hashbrown, a kitten with supravalvular mitral stenosis. This hybrid balloon valvuloplasty, a first-of-its-kind procedure for such a small and young patient, involved a collaborative effort by professionals.

The rise in innovative treatments and the increasing awareness of the importance of heart health in pets is driving growth in the veterinary cardiology industry. Pet owners increasingly seek specialized care for their animals, recognizing the availability of life-extending treatments that were once only accessible to humans. As a result, the demand for advanced veterinary cardiology services is expected to grow, further solidifying its place as a crucial component of modern veterinary medicine.

For example, in June 2024, the Indian Council for Agricultural Research published a study examining the incidence of cardiac arrhythmias in 435 dogs with a history of generalized diseases over 14 months from July 2022 to September 2023. The assessment was aimed to determine the occurrence of arrhythmias and found that 114 dogs (26.21%) displayed various types, including atrial fibrillation (30.70%), ST-segment coving, sinus arrest (9.65% each), and ST-segment elevation (8.77% each).

Ongoing Clinical Trials in Veterinary Field

Source: American Veterinary Medical Association, Secondary Research, Grand View Research

Market Concentration

The U.S. companion animal cardiac pharmaceuticals industry is moderately growing and experiencing accelerating growth. Increasing research and development in veterinary cardiology is important for market growth. With increased knowledge about cardiovascular diseases in animals, increased research is being done to develop innovative diagnostic devices, treatments, and therapies for pets with heart diseases. Increased research is propelling advances in preventing and controlling cardiovascular diseases in pets and other animals.

For example, in August 2024, the Atlantic Veterinary College at the University of Prince Edward Island launched a clinical trial in Canada to evaluate propranolol, a medication commonly prescribed to children for treating cardiac tumors in dogs. The analysis determines if propranolol can shrink tumors and improve the quality of life for affected canines. Moreover, investment in clinical trials for new veterinary cardiovascular medicines and medical devices is accelerating the approval of innovative products to speed up faster. These processes are important since they guarantee veterinarians maximum access to the most effective and modern animal treatments.

U.S. Companion Animal Cardiac Pharmaceuticals Industry Characteristics

The U.S. companion animal cardiac pharmaceuticals industry exhibits a moderate to high degree of innovation, driven by the development of novel drug formulations such as extended-release and combination therapies, improved drug delivery systems like chewable and transdermal patches, and the adaptation of human cardiac drugs into species-specific veterinary formulations.

Mergers and acquisitions (M&A) in the U.S. companion animal cardiac pharmaceuticals industry significantly impact market dynamics by enabling companies to expand their product portfolios, strengthen R&D capabilities, and enhance distribution networks. Through strategic acquisitions, larger firms can integrate innovative cardiac drug technologies or formulations developed by smaller companies, and expanding therapeutic offerings. For instance, in September 2024, Boehringer Ingelheim acquired Saiba Animal Health AG that enhances the company’s R&D pipeline in pet therapeutics, addressing chronic conditions.

Regulations play a crucial role in shaping the U.S. companion animal cardiac pharmaceuticals industry by ensuring the safety, efficacy, and quality of veterinary drugs. The FDA’s Center for Veterinary Medicine (CVM) establishes strict guidelines for drug approval, manufacturing, labeling, and post-market surveillance, which encourages companies to invest in robust clinical trials and maintain high product standards. While regulatory compliance can increase development timelines and costs, it also fosters trust among veterinarians and pet owners, promoting wider adoption of approved therapies.

In the U.S. companion animal cardiac pharmaceuticals industry, product substitutes include a range of alternative treatment options that can either complement or replace pharmaceutical therapies. These substitutes include nutraceuticals such as omega-3 fatty acids, taurine, and Coenzyme Q10, which are used to support heart health in pets. Lifestyle and dietary management, such as low-sodium diets formulated for cardiac conditions, also serve as non-pharmaceutical interventions.

Pharmaceuticals Insights

The pimobendan segment led the market with the largest revenue share of 48.38% in 2024, due to its proven effectiveness in managing congestive heart failure (CHF) in dogs, especially those with conditions like dilated cardiomyopathy (DCM) and myxomatous mitral valve disease (MMVD). Heart disease affects approximately 10% of dogs during their lifetime, with myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM) being the most prevalent forms. Pimobendan has become a vital pharmaceutical intervention in the management of these conditions, significantly improving survival time and quality of life in affected dogs.

Pimobendan is a calcium sensitizer and phosphodiesterase-3 (PDE3) inhibitor that enhances cardiac contractility and vasodilation. Initially approved under the brand name Vetmedin in 2007, it is widely used in dogs with mild to severe congestive heart failure (CHF) caused by MMVD or DCM. In 2022, Vetmedin-CA1 received conditional FDA approval for delaying the onset of CHF in dogs diagnosed with preclinical (Stage B2) MMVD. A landmark study indicated that early intervention with Vetmedin-CA1 could prolong the asymptomatic period by an average of 15 months.

The others segment is expected to grow at the fastest CAGR over the forecast period. Others include vasodilators, antithrombotic/anticoagulants, and anti-arrhythmic drugs. Beyond commonly used treatments like pimobendan and the spironolactone-benazepril combination, several other medications have emerged, reflecting advancements in species-specific cardiac care. Felycin-CA1 (sirolimus delayed-release tablets), conditionally approved by the FDA on March 14, 2025, is the first drug indicated for cats with hypertrophic cardiomyopathy (HCM). HCM, the most prevalent feline cardiac condition, leads to thickening of the left ventricle and can progress to heart failure, thromboembolism, or sudden death.

Animal Type Insights

The dogs segment accounted for the largest market revenue share in 2024. The veterinary cardiology market for dogs is experiencing robust growth, driven by increasing pet ownership, heightened awareness of cardiac health, and advancements in treatment. Key players in the field include CVCA Veterinary Cardiac Care, VCA Animal Hospitals, and Mars Petcare, who are at the forefront of developing innovative solutions for canine heart conditions. Moreover, in November 2024, Boehringer Ingelheim, launched Vetmedin Solution, the first FDA-approved oral solution for treating congestive heart failure in dogs caused by myxomatous mitral valve disease or dilated cardiomyopathy. All these factors contribute to the market growth.

The cats segment is anticipated to grow at the fastest CAGR during the forecast period, due to increased pet longevity, rising cardiovascular disease prevalence. Key players include Boehringer Ingelheim, IDEXX, and FUJIFILM, driving innovation through AI integration, minimally invasive procedures, and advanced imaging techniques. A study conducted in October 2022, the RAPACAT trial which results, showcased a novel delayed-release rapamycin formulation for feline hypertrophic cardiomyopathy (HCM). This randomized, placebo-controlled trial involved 43 client-owned cats with subclinical HCM, administered once-weekly doses over six months. The study found that low-dose rapamycin significantly reduced left ventricular myocardial wall thickness compared to placebo, indicating potential to prevent or delay HCM progression. The treatment was well-tolerated with no significant adverse effects.

Indication Insights

The congestive heart failure (CHF) segment led the market with the largest revenue share of 38.33% in 2024. This growth is attributed to the increasing prevalence of valvular heart disease and dilated cardiomyopathy, which lead to volume overload, pressure overload, or both, ultimately resulting in CHF. These conditions cause enlargement of the heart chambers and impaired contractility, leading to poor cardiac function and eventual CHF. Frequent studies and advancements in treating CHF contribute to the growth of this segment. For instance, in 2024, the U.S. Food and Drug Administration (FDA) approved Pimomedin, the first generic version of pimobendan chewable tablets, for managing congestive heart failure (CHF) in dogs. This approval provides a more affordable treatment option for canine patients suffering from conditions like myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM), which are the leading causes of CHF in dogs.

The others segment is expected to grow at the fastest CAGR over the forecast period. Other indications such as pulmonary hypertension (PH), pericardial diseases, and congenital heart defects (CHDs) are notable for their prevalence and clinical importance. PH, characterized by elevated blood pressure in the pulmonary arteries, often arises secondary to conditions like degenerative mitral valve disease (DMVD), chronic respiratory disorders, or heartworm infections. In addition, in 2024, a significant study published in the American Journal of Veterinary Research analyzed 66 cases of canine PH, revealing that affected dogs were generally older and had lower body weights than non-PH counterparts. The study also found a higher incidence of respiratory comorbidities in the PH group, emphasizing the multifactorial nature of the disease and the need for comprehensive diagnostic approaches.

End Use Insights

The veterinary hospitals & clinics segment led the market with the largest revenue share of 60.43% in 2024. This prominence is attributed to the increasing prevalence of cardiac conditions in companion animals, necessitating specialized care in these facilities. In addition, the growing number of veterinary hospitals, coupled with rising pet health awareness and frequent routine checkups, increases the demand for cardiac drugs. As more pet owners seek specialized care for chronic conditions like congestive heart failure or mitral valve disease, veterinary hospitals significantly contribute to the rising adoption of effective pharmaceutical therapies, thus driving market expansion.

The others segment is anticipated to grow at the fastest CAGR during the forecast period. Beyond veterinary hospitals and clinics, academic and research institutions, mobile veterinary units, and specialty referral centers are pivotal in advancing the veterinary cardiology market. Academic and research institutions contribute by advancing scientific knowledge and drug development through clinical trials, pharmacological research, and collaboration with veterinary pharmaceutical companies. Their work leads to the innovation of more effective and targeted cardiac therapies, which ultimately reach the market.

Distribution Channel Insights

The hospital/ clinic pharmacy segment accounted for the largest market revenue share in 2024. This growth is driven by the increasing prevalence of cardiac conditions in companion animals, necessitating immediate access to specialized medications. Veterinary hospitals and clinics equipped with in-house pharmacies ensure timely dispensing of critical cardiac drugs, facilitating prompt treatment initiation and adherence to prescribed regimens. Integrating pharmacy services within clinical settings enhances the continuum of care, allowing for seamless coordination between diagnosis, prescription, and medication dispensing. This model improves patient outcomes, and fosters trust and convenience for pet owners seeking comprehensive cardiac care for their animals.

The e-commerce segment is expected to grow at the fastest CAGR over the forecast period,driven by the acceleration of e-commerce, shifting client expectations, and the integration of digital prescribing technologies. While traditional in-clinic pharmacies remain a key point of sale for cardiac medications, especially those required urgently, the rise of online veterinary pharmacies and third-party platforms is reshaping how and where clients access products for their pets’ heart health.

Country Insights

U.S. Companion Animal Cardiac Pharmaceuticals Market Trends

The companion animal cardiac pharmaceuticals market in the U.S. is experiencing rapid growth, supported by a robust healthcare infrastructure and high pet care expenditure. According to the American Pet Products Association, over USD 151.9 billion was spent on pets in 2024, with a growing portion directed toward specialized veterinary services. Renowned institutions such as UC Davis Veterinary Medical Teaching Hospital and Colorado State University played a vital role in advancing clinical research and service availability. The availability of board-certified veterinary cardiologists and well-organized specialty referral networks enhanced access to advanced cardiac care.

Key U.S. Companion Animal Cardiac Pharmaceuticals Company Insights

The companion animal cardiac pharmaceuticals market in the U.S. is moderately consolidated, with key players competing based on product innovation, clinical efficacy, pricing strategies, and distribution reach. Leading companies focus on expanding their cardiac portfolios through the development of advanced formulations like extended release or palatable tablets to enhance compliance and treatment outcomes. Strategic collaborations, mergers and acquisitions, and continual investment in R&D are commonly employed to strengthen market positioning.

Recent Developments

• In February 2024, Boehringer Ingelheim partnered with Veeva Systems to enhance its clinical and regulatory operations in animal health. This collaboration aims to streamline clinical execution and accelerate the development of new veterinary medicines, including those targeting cardiovascular diseases in animals.

• In December 2022, Ceva acquired two Argentine companies, Zoovet and Biotecnofe. This strategic acquisition provided Ceva with access to a biotechnology campus in Santa Fe, Argentina, enhancing its capabilities in pharmaceutical innovation.

• In September 2024, Zoetis expanded its global capability center in Hyderabad, India, to strengthen its regional presence.

U.S. Companion Animal Cardiac Pharmaceuticals Market